Search Within

Michael Morris

Formats
  1. Meeting Abstract (276)
  2. Journal Article (268)
  3. Review (21)
  4. Book Section (6)
  5. Editorial (6)
  6. Correspondence (4)
  7. Guidelines (3)
  8. Miscellaneous (2)
  9. Conference Paper (1)
  10. Research Letter (1)
Groups
  1. Department of Medicine (588)
  2. Genitourinary Oncology Service (588)
  3. Solid Tumor Oncology Division (588)
  4. Radiology, Department of (165)
  5. GSK Faculty (161)
  6. Molecular Imaging and Therapy Service (142)

More Groups

People
  1. Howard Scher (217)
  2. Steven Larson (93)
  3. Susan Slovin (90)
  4. Dana Rathkopf (79)
  5. Daniel Danila (54)
  6. Glenn Heller (54)

More People

Years
  1. 2025 (29)
  2. 2024 (50)
  3. 2023 (40)
  4. 2022 (50)
  5. 2021 (42)
  6. 2020 (35)

More Years

Publications
  1. Journal of Clinical Oncology (240)
  2. Journal of Nuclear Medicine (45)
  3. Clinical Cancer Research (33)
  4. Annals of Oncology (30)
  5. Cancer (18)
  6. European Urology (18)

More Publications

Publishers
  1. American Society of Clinical Oncology (250)
  2. Society of Nuclear Medicine (45)
  3. American Association for Cancer Research (43)
  4. Oxford University Press (41)
  5. Elsevier Science, Inc. (40)
  6. Elsevier Inc. (27)

More Publishers

Results (588)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Randomized phase 2 trial of abiraterone acetate plus prednisone, degarelix, or the combination in men with biochemically recurrent prostate cancer after radical prostatectomy
    Journal Article

    Autio, K. A.; Antonarakis, E. S.; Mayer, T. M.; Shevrin, D. H.; Stein, M. N.; Vaishampayan, U. N.; Morris, M. J.; Slovin, S. F.; Heath, E. I.; Tagawa, S. T.; more...
    European Urology Open Science (2021)

    Fulltext@MSK | Save
  • Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION)
    Meeting Abstract

    Morris, M. J.; De Bono, J. S.; Chi, K. N.; Fizazi, K.; Herrmann, K.; Rahbar, K.; Tagawa, S. T.; Nordquist, L. T.; Vaishampayan, N.; El-Haddad, G.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • PSMAddition: A phase III trial to compare treatment with (177)Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer
    Meeting Abstract

    Tagawa, S. T.; Sartor, O.; Saad, F.; Sakharova, O.; de Bono, J.; Feng, F.; Fizazi, K.; Morris, M. J.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • PSMAfore: A phase III study to compare (177)Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naive patients with mCRPC
    Meeting Abstract

    Morris, M. J.; Sartor, O.; Chi, K. N.; de Bono, J. S.; Shore, N. D.; Crosby, M.; Dalal, D.; Fizazi, K.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of (177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Fizazi, K.; Herrmann, K.; Krause, B. J.; Rahbar, K.; Chi, K. N.; Morris, M. J.; Sartor, O.; Tagawa, S. T.; Kendi, A. T.; Vogelzang, N. J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Prospective evaluation of clinical outcomes using a multiplex liquid biopsy targeting diverse resistance mechanisms in metastatic prostate cancer
    Journal Article

    Sperger, J. M.; Emamekhoo, H.; McKay, R. R.; Stahlfeld, C. N.; Singh, A.; Chen, X. E.; Kwak, L.; Gilsdorf, C. S.; Wolfe, S. K.; Wei, X. X.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Therapeutic implications of germline testing in patients with advanced cancers
    Journal Article

    Stadler, Z. K.; Maio, A.; Chakravarty, D.; Kemel, Y.; Sheehan, M.; Salo-Mullen, E.; Tkachuk, K.; Fong, C. J.; Nguyen, B.; Erakky, A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Randomized phase III trial of gemcitabine and cisplatin with bevacizumab or placebo in patients with advanced urothelial carcinoma: Results of CALGB 90601 (Alliance)
    Journal Article

    Rosenberg, J. E.; Ballman, K. A.; Halabi, S.; Atherton, P. J.; Mortazavi, A.; Sweeney, C.; Stadler, W. M.; Teply, B. A.; Picus, J.; Tagawa, S. T.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase II, nonrandomized open trial assessing pain efficacy with radium-223 in symptomatic metastatic castration-resistant prostate cancer
    Journal Article

    McHugh, D.; Tagawa, S.; Moryl, N.; Milowsky, M.; Heller, G.; Osborne, J.; Rathkopf, D.; Basch, E.; Pandit-Taskar, N.; Morris, M. J.
    Clinical Genitourinary Cancer (2021)

    Fulltext@MSK | Save
  • Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer
    Journal Article

    Sartor, O.; de Bono, J.; Chi, K. N.; Fizazi, K.; Herrmann, K.; Rahbar, K.; Tagawa, S. T.; Nordquist, L. T.; Vaishampayan, N.; El-Haddad, G.; more...
    New England Journal of Medicine (2021)

    Fulltext@MSK | Save